DE60144401D1 - Aspirin-ausgelöste Lipidmediatoren - Google Patents

Aspirin-ausgelöste Lipidmediatoren

Info

Publication number
DE60144401D1
DE60144401D1 DE60144401T DE60144401T DE60144401D1 DE 60144401 D1 DE60144401 D1 DE 60144401D1 DE 60144401 T DE60144401 T DE 60144401T DE 60144401 T DE60144401 T DE 60144401T DE 60144401 D1 DE60144401 D1 DE 60144401D1
Authority
DE
Germany
Prior art keywords
aspirin
lipid mediators
triggered lipid
triggered
mediators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144401T
Other languages
English (en)
Inventor
Clary B Clish
Charles N Serhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE60144401D1 publication Critical patent/DE60144401D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE60144401T 2000-02-16 2001-02-16 Aspirin-ausgelöste Lipidmediatoren Expired - Lifetime DE60144401D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18307800P 2000-02-16 2000-02-16
US23881400P 2000-10-06 2000-10-06

Publications (1)

Publication Number Publication Date
DE60144401D1 true DE60144401D1 (de) 2011-05-19

Family

ID=26878731

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60144401T Expired - Lifetime DE60144401D1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste Lipidmediatoren
DE60124256T Expired - Lifetime DE60124256T3 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60124256T Expired - Lifetime DE60124256T3 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Country Status (12)

Country Link
US (5) US6670396B2 (de)
EP (2) EP1296923B3 (de)
JP (5) JP4932116B2 (de)
CN (4) CN1202068C (de)
AT (2) ATE344226T1 (de)
AU (4) AU2001238468B2 (de)
CA (1) CA2400462C (de)
DE (2) DE60144401D1 (de)
HK (1) HK1105948A1 (de)
IL (1) IL151299A0 (de)
MX (1) MXPA02007915A (de)
WO (1) WO2001060778A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296923B3 (de) * 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-ausgelöste lipidmediatoren
EP1268393A2 (de) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
AU2002255627B2 (en) * 2001-02-27 2008-01-17 The Regents Of The University Of Michigan Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
DK1406698T3 (da) * 2001-03-02 2009-02-09 Brigham & Womens Hospital Lipoxinanaloger som nye inhibitorer af angiogenese
DE60236467D1 (de) 2001-03-02 2010-07-01 Brigham And Women S Hospital B Lipoxinanaloge als neuartige Restenose-Hemmer
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
US20040176451A1 (en) * 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
CA2467580C (en) * 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7030159B2 (en) * 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
EP2022775B1 (de) * 2002-04-01 2014-10-15 University of Southern California Mehrfach ungesättigte Eicosanoide
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
AU2003238240A1 (en) * 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
EP2216318B1 (de) 2002-08-12 2018-10-10 Brigham And Women's Hospital Resolvine: Biovorlagen für therapeutische Eingriffe
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
CA2499501A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
ES2349927T3 (es) * 2003-07-07 2011-01-13 Hill's Pet Nutrition, Inc. Composiciones para mejorar el estado oxidativo en gatos.
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
EP2801354B1 (de) * 2004-10-08 2017-02-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
KR20070090928A (ko) * 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
WO2007061783A1 (en) 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
AU2007243282A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
CN101528218A (zh) * 2006-07-19 2009-09-09 雷索维克斯药品公司 治疗粘膜炎的组合物和方法
WO2008057283A2 (en) * 2006-10-26 2008-05-15 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
US20110190389A1 (en) * 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
AU2008312006B2 (en) * 2007-10-12 2013-12-12 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxyliptin compounds for the treatment of ophthalmic conditions
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
EP2280928B1 (de) 2008-05-01 2018-07-25 Complexa Inc. Vinylsubstituierte fettsäuren
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
JPWO2010021385A1 (ja) * 2008-08-22 2012-01-26 持田製薬株式会社 Ａｎｃａ関連血管炎治療薬
EP2344441B1 (de) 2008-09-16 2016-02-17 The Brigham And Women's Hospital Inc. 7,14-dihydroxydocosahexaensäureverbindungen
US20110190242A1 (en) * 2008-09-23 2011-08-04 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2010095706A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2011014261A1 (en) * 2009-07-31 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
US20130137767A1 (en) * 2010-02-02 2013-05-30 Dsm Ip Assets B.V. Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
WO2012023254A1 (ja) * 2010-08-19 2012-02-23 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
EP2744491B1 (de) 2011-08-19 2020-07-29 The University of Utah Research Foundation Kombinationstherapie mit nitrierten lipiden und inhibitoren des renin-angiotensin-aldosteron-systems
FR2979824A1 (fr) * 2011-09-13 2013-03-15 Vetinnov Composition a usage humain ou veterinaire.
JP5969186B2 (ja) * 2011-09-15 2016-08-17 出光興産株式会社 Ｇｐｒ１１９アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤
WO2013044176A2 (en) * 2011-09-23 2013-03-28 University Of Southern California Methods and compositions for the treatment of ischemic stroke
EP2814479B1 (de) 2012-02-15 2019-09-04 Anida Pharma Inc. Verfahren zur behandlung amyotropher lateralsklerose
ES2946109T3 (es) 2012-05-10 2023-07-12 Solutex Na Llc Aceites con actividad antiinflamatoria que contienen mediadores pro-resolutivos especializados naturales y sus precursores
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
CA3050298A1 (en) 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US11058659B2 (en) 2013-02-22 2021-07-13 University Of Southern California Methods and compositions for the treatment of ophalmic diseases and disorders
JP6295278B2 (ja) 2013-02-28 2018-03-14 アニダ ファーマ インコーポレイテッド 聴器毒性を治療する方法
WO2015071766A1 (en) 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
KR20160132372A (ko) * 2014-01-10 2016-11-18 디그너티 사이언스 리미티드 15-hepe를 포함하는 약제학적 조성물 및 이를 이용하는 천식 및 폐 장애의 치료 방법
BR112016028518A2 (pt) 2014-06-04 2017-08-22 Dignity Sciences Ltd composições farmacêuticas que compreendem dgla e uso do mesmo
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN114377138A (zh) 2015-03-18 2022-04-22 福塞斯儿童牙科医院 使用脂氧素、消退素及其类似物稳定动脉粥状硬化斑块的方法
EP3865484B1 (de) 2015-07-07 2023-11-08 H. Lundbeck A/S Pde9-inhibitor mit imidazopyrazinon-rückgrat zur behandlung von peripheren erkrankungen
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
BR112018006687A2 (pt) 2015-10-02 2018-10-09 Complexa Inc prevenção, tratamento e reversão de doenças utilizando montantes terapeuticamente eficazes de ácidos graxos ativos
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
FI3373976T3 (fi) 2015-11-10 2024-03-25 Sun Pharmaceutical Ind Ltd Topikaalisia formulaatioita ja niiden käyttöjä
WO2017205582A1 (en) 2016-05-27 2017-11-30 Forsyth Dental Infirmary For Children Compositions and methods of treating cancer using lipid agonists and receptors thereof
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
CN105924338B (zh) * 2016-06-17 2019-03-01 中科瑞奥能源科技股份有限公司 丁醇尾气回收工艺与系统
WO2017223447A1 (en) 2016-06-23 2017-12-28 The Regents Of The University Of Michigan 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
CA3055093A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019182191A1 (ko) * 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
WO2020076578A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
BR112021010335A2 (pt) * 2018-11-30 2021-11-16 Evonik Operations Gmbh Preparação que compreende uma cepa probiótica e um componente de ácido graxo poli-insaturado
EP3946308A4 (de) * 2019-04-04 2022-12-14 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Sehr langkettige mehrfach ungesättigte fettsäuren, elovanoidhydroxylierte derivate und verfahren zur verwendung
EP4032914A4 (de) * 2019-09-20 2023-10-18 Kyungpook National University Industry-Academic Cooperation Foundation Antikörper zum detektieren der acetylierung von cox2-protein und verwendungen davon
IL297114A (en) * 2020-04-03 2022-12-01 Afimmune Ltd Preparations that include 15-hepe for the treatment or prevention of hematological disorders, and/or related diseases
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466701A (en) 1892-01-05 Hiram ezkiel payne
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
GB2033745B (en) 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4442099A (en) 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4567290A (en) 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5136501A (en) 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
EP0573423A4 (en) * 1990-05-07 1994-06-01 Barry I Bockow Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
JPH0425036A (ja) 1990-05-16 1992-01-28 Mitsubishi Electric Corp マイクロ波半導体装置
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
CA2112399C (en) 1991-06-24 2004-06-29 Antonio Ferrante Methods and compositions for treating malaria and other diseases
US5177046A (en) 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5409955A (en) 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
JP2536436B2 (ja) 1993-11-19 1996-09-18 日本電気株式会社 モ―ルド型半導体装置
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5870717A (en) 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
ES2311571T3 (es) 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
US5878400A (en) 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
US6602817B1 (en) 1998-10-23 2003-08-05 University Of Southern California Combination approach to chiral reagents or catalysts having amine or amino alcohol ligands
CA2259203C (en) 1996-06-28 2008-04-29 Nicos A. Petasis Method for the synthesis of amines and amino acids with organoboron derivatives
US5890138A (en) 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US5878423A (en) 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6030715A (en) 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
EP1075252A2 (de) 1998-05-07 2001-02-14 ELAN CORPORATION, Plc Mikroemulsion frei von lösungsmittel und co-lösungsmittel und emulsionvorkonzentrat als wirkstoff freisetzungssytemen
US6377937B1 (en) 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (de) 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
US6272474B1 (en) 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
EP2236140A1 (de) 1999-03-18 2010-10-06 The Brigham and Women's Hospital, Inc. Regulierung der Phospholipase d Aktivität
ATE310512T1 (de) 1999-03-18 2005-12-15 Brigham & Womens Hospital Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion
US6271435B1 (en) 1999-03-18 2001-08-07 Brigham & Women's Hospital, Inc. Leukotriene B4 receptor transgenic mice
CA2365204C (en) 1999-03-18 2009-10-27 Brigham And Women's Hospital Lipoxin compounds and their use
US6427132B1 (en) 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
EP1296923B3 (de) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-ausgelöste lipidmediatoren
EP1268393A2 (de) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
US6473314B1 (en) 2000-08-03 2002-10-29 Powerwave Technologies, Inc. RF power amplifier assembly employing multi-layer RF blocking filter
US20020074162A1 (en) 2000-12-15 2002-06-20 Bor-Ray Su Substrate layout method and structure for reducing cross talk of adjacent signals
DK1406698T3 (da) 2001-03-02 2009-02-09 Brigham & Womens Hospital Lipoxinanaloger som nye inhibitorer af angiogenese
US20040044028A1 (en) 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US7030159B2 (en) 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
CA2467580C (en) 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
EP2022775B1 (de) * 2002-04-01 2014-10-15 University of Southern California Mehrfach ungesättigte Eicosanoide
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
AU2003238240A1 (en) 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP2216318B1 (de) 2002-08-12 2018-10-10 Brigham And Women's Hospital Resolvine: Biovorlagen für therapeutische Eingriffe
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
WO2005013908A2 (en) 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
US20050238589A1 (en) 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
CN101528218A (zh) 2006-07-19 2009-09-09 雷索维克斯药品公司 治疗粘膜炎的组合物和方法

Also Published As

Publication number Publication date
US7737178B2 (en) 2010-06-15
AU2009202071A1 (en) 2009-06-18
EP1296923B3 (de) 2012-04-11
CN102010324A (zh) 2011-04-13
DE60124256D1 (de) 2006-12-14
US7709669B2 (en) 2010-05-04
AU2001238468B2 (en) 2006-07-06
JP5973503B2 (ja) 2016-08-23
WO2001060778A3 (en) 2003-01-16
AU3846801A (en) 2001-08-27
AU2006225252A2 (en) 2006-11-02
US20040059144A1 (en) 2004-03-25
JP4932116B2 (ja) 2012-05-16
EP1296923B1 (de) 2006-11-02
JP2010248213A (ja) 2010-11-04
ATE344226T1 (de) 2006-11-15
CA2400462C (en) 2011-09-27
HK1105948A1 (en) 2008-02-29
US7053230B2 (en) 2006-05-30
US20020055538A1 (en) 2002-05-09
CN1951899A (zh) 2007-04-25
CN100357244C (zh) 2007-12-26
US20090149538A1 (en) 2009-06-11
EP1762557A2 (de) 2007-03-14
US6670396B2 (en) 2003-12-30
AU2006225252B2 (en) 2009-02-26
US20070049639A1 (en) 2007-03-01
DE60124256T3 (de) 2012-09-20
EP1296923A2 (de) 2003-04-02
CN1951899B (zh) 2012-02-01
JP2015007046A (ja) 2015-01-15
WO2001060778A9 (en) 2002-10-24
CN1469858A (zh) 2004-01-21
JP2003525880A (ja) 2003-09-02
AU2009202071B2 (en) 2011-07-07
EP1762557A3 (de) 2007-11-07
US8349896B2 (en) 2013-01-08
CN102010324B (zh) 2014-04-02
JP2019108348A (ja) 2019-07-04
WO2001060778A2 (en) 2001-08-23
CN1680259A (zh) 2005-10-12
EP1762557B1 (de) 2011-04-06
IL151299A0 (en) 2003-04-10
JP2016006057A (ja) 2016-01-14
CN1202068C (zh) 2005-05-18
US20100216882A1 (en) 2010-08-26
DE60124256T2 (de) 2007-05-31
MXPA02007915A (es) 2005-06-20
AU2006225252A1 (en) 2006-11-02
ATE504557T1 (de) 2011-04-15
CA2400462A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
DE60144401D1 (de) Aspirin-ausgelöste Lipidmediatoren
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
ITMI20001317A0 (it) Procedimento per la purificazione di diacereina.
ES1049731Y (es) Dispositivo para la administracion de farmacos.
IT1318631B1 (it) Procedimento per la produzione di alfa-olefine.
TH103000082A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000093A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000050EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000049EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000080A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000048A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000046EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000045EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000043EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000030A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH101000439A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000075EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000025A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000023A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000520A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000021A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000068EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH101001395A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000076A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000062EX (th) สิทธิบัตรยังไม่ประกาศโฆษณา